The results of this study not only highlight the overall effectiveness of these bioreactors but also illustrate the potential of maintaining the same outcome when scaled up to industrial production, which has many implications for faster vaccine production. The systems yielded approximately 39.2 and 18.0 μg/ml of HA protein with the 10-liter TideCell002 from the H5N1 clade II and H7N9 CVVs, respectively. The performances of between BelloCell and TideCell were similar in cell growth, the average MDCK cell doubling time was slightly decreased to 25 hours. All culturing conditions were tested and scaled to 10 L industrial-scale bioreactor known as TideCell002. A novel bench-scale bioreactor named BelloCell bioreactor was used in the study. Madin-Darby canine kidney (MDCK) cells were used for the production of these influenza CVVs. In this study, two novel disposable cell-based bioreactors, BelloCell and TideCell, were used to produce H5N1 clade II and H7N9 candidate vaccine viruses (CVVs). For example, they enable a short production time, allow for the handling highly pathogenic influenza in closed environments, and can be easily scaled up. These novel bioreactors, used for cell-based vaccine production, possess various advantages. A potential solution for this problem is the use of cell-based bioreactors for rapid vaccine production. it is crucial to develop a rapid production platform to meet this surge demand against any possible influenza pandemic. These highly pathogenic influenza viruses could potentially cause a worldwide pandemic. In addition, an outbreak of another new and highly pathogenic influenza virus (H7N9) occurred in 2013 in China. According to the WHO bulletin report, the H5N1 virus is a zoonotic disease threat that has infected more than 850 humans, causing over 450 deaths. Since 1997, the highly pathogenic influenza H5N1 virus has spread from Hong Kong.